AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas
vMiX™ is a vectorized RNA interference (RNAi) platform combining knockdown, cell-specific expression with the flexibility to target multiple genes
Update follows recent positive AVB-406 preclinical data presented at ASGCT, supporting the broad therapeutic potential of the vMiX platform including initiation of clinical trials in 2026
AviadoBio Ltd. ("AviadoBio"), a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, and King's College London today announced an expanded license agreement providing AviadoBio exclusive rights to apply the vMiX™ RNAi gene silencing platform across all human therapeutic areas. Building on their 2020 agreement, which granted AviadoBio rights to apply the platform to its pipeline of gene therapies in neurological diseases, this expansion opens potential applications across cardiovascular disease, nephrology, oncology and a range of other indications beyond the central nervous system.
The vMiX platform is designed to enable targeted, durable gene silencing using AAV as a delivery vehicle. By harnessing the natural cellular mechanism of RNAi, vMiX has the potential for sustained reduction of disease-causing gene expression following a single administration. The platform has the potential to silence up to three genes simultaneously and enable ‘silencing and replacement’ via inclusion of a transgene sequence within the construct. Silencing activity is tightly controlled to regions of disease pathology using tissue- or cell-specific promoters. The expanded license enables broader application of the platform through strategic collaborations and partnerships.
